NetworkNewsBreaks – CNS Pharmaceuticals Inc.’s
Post# of 368
(Total Views: 209)
Posted On: 05/05/2022 4:03:45 PM
NetworkNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Demonstrating ‘Encouraging Promise in Treatment of GBM’
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical cancer drug developer, recently reported new advances in its rollout of a global clinical trial described as “potentially pivotal” in producing a treatment for an aggressive brain cancer, glioblastoma multiforme (“GBM”). On average, GBM is nearly 100% fatal just over a year into diagnosis. “CNS announced that France’s regulatory agencies have granted the company authority to pursue patient recruitment in the country…. France’s approval comes on the heels of similar authorization in Switzerland, where Swissmedic, the Swiss agency for therapeutic products, joined swissethics, the umbrella organization of the cantonal Ethics Committees (‘ECs’), in greenlighting the clinical studies,” a recent article reads. “‘The data Berubicin has shown to date demonstrates encouraging promise in treatment of GBM. Patients and families are desperate for a viable treatment option that provides benefits, and I look forward to further exploring Berubicin’s potential,’ stated CNS’s national coordinating investigator partner in Switzerland, Professor Michael Weller, MD, of the University Hospital Zurich.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical cancer drug developer, recently reported new advances in its rollout of a global clinical trial described as “potentially pivotal” in producing a treatment for an aggressive brain cancer, glioblastoma multiforme (“GBM”). On average, GBM is nearly 100% fatal just over a year into diagnosis. “CNS announced that France’s regulatory agencies have granted the company authority to pursue patient recruitment in the country…. France’s approval comes on the heels of similar authorization in Switzerland, where Swissmedic, the Swiss agency for therapeutic products, joined swissethics, the umbrella organization of the cantonal Ethics Committees (‘ECs’), in greenlighting the clinical studies,” a recent article reads. “‘The data Berubicin has shown to date demonstrates encouraging promise in treatment of GBM. Patients and families are desperate for a viable treatment option that provides benefits, and I look forward to further exploring Berubicin’s potential,’ stated CNS’s national coordinating investigator partner in Switzerland, Professor Michael Weller, MD, of the University Hospital Zurich.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)